Today we are incredibly proud to conclude the clinical trial Solvemed has run jointly with Queen Mary University of London & Barts Health NHS Trust, in collaboration with Professor Alastair Noyce's clinical neuroscience research group investigating the relationship of Solvemed’s novel digital biomarkers and the onset and development of Parkinson’s disease.
As part of this study, our Team gathered data using Solvemed’s artificial intelligence-based software as medical device (SaMD) allowing to perform brain health assessment and accurately measure various neuro-ophthalmic digital biomarkers, including pupil reactivity and eye movements.
Special thanks to Charlotte Edwards and Dr Alexandra Zirra for their amazing cooperation during their time working diligently with our patients. Moreover, thanks to our Team, especially Michal Wlodarski and Dr Ivo John for their excellent leadership and help with coordinating the study. We cannot forget Dr James Neffendorf, one of our Medical Directors and a long-standing mentor for his generosity at the conception phases of the study and for his instrumental strategic input around the study design. This clinical trial brings hope to patients and clinical researchers alike, further building the potential for earlier and more accurate diagnosis using ocular biomarkers, and – in consequence – novel tools to develop improved treatment options! Parkinson's disease is the fastest-growing neurological disease worldwide, affecting 10M people globally with limited diagnostic and treatment options available.
We are incredibly happy to be able to advance the frontier of innovation in this exciting space, bringing responsible AI into healthcare through innovative software as medical devices. With encouraging initial trial results, we expect to publish the outcomes of this study shortly.
We guarantee no spam . One high-quality email per month packed with valuable updates, exciting news. Join now!